Pharmacy Friday Pearls

MARCH 4, 2022

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Hospitals Packaging Immunization 40

PharmaShots

APRIL 25, 2023

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

ISPE

JULY 6, 2023

billion US in 2021 to $1.9 1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. In 2021, CONTINUUS Pharmaceuticals secured a$69.3 This is demonstrated by the rise from $1.05

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Dosage Pharmaceutical Companies Pharmaceutical Companies 52